EMERGENT BIOSOLUTIONS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
EMERGENT BIOSOLUTIONS INC. (EBS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $100.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2024-08-07
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-06-30 was $100.00K, a 75.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-03-31 was $500.00K, a 66.67% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-06-30 was $400.00K.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-03-31 was $300.00K.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $200.00K, a 92.31% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $2.60M, a 10.34% decline from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $2.90M, a 90.85% decline from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was $31.70M, a 27.82% increase from fiscal 2019.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-06-30 | $100.00K 10-Q · filed 2024-08-07 | $600.00K derived: sum of 2 quarters · filed 2024-08-07 | ||||
| 2024-03-31 | $500.00K 10-Q · filed 2024-08-07 | |||||
| 2023-12-31 | $200.00K 10-K · filed 2024-03-08 | |||||
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-07 | $400.00K 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $300.00K 10-Q · filed 2024-08-07 | $1.50M 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $2.60M 10-K · filed 2024-03-08 | |||||
| 2021-12-31 | $2.90M 10-K · filed 2024-03-08 | |||||
| 2020-12-31 | $31.70M 10-K/A · filed 2023-12-11 | |||||
| 2019-12-31 | $24.80M 10-K · filed 2021-02-19 | |||||
| 2018-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $1.43M derived: sum of 2 quarters · filed 2020-02-25 | $2.11M derived: sum of 3 quarters · filed 2020-02-25 | $3.10M 10-K · filed 2020-02-25 | $3.10K 10-K · filed 2019-02-22 | |
| 2018-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $928.00K derived: sum of 2 quarters · filed 2018-11-02 | $1.92M 10-Q · filed 2018-11-02 | $574.80K derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2018-06-30 | $685.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $1.67M 10-Q · filed 2018-08-03 | $331.80K derived: sum of 3 quarters · filed 2019-02-22 | $1.25M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2018-03-31 | $989.00K 10-Q · filed 2018-05-04 | -$353.20K derived: sum of 2 quarters · filed 2019-02-22 | $563.80K derived: sum of 3 quarters · filed 2019-02-22 | $796.80K derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$425.20K derived: sum of 2 quarters · filed 2019-02-22 | -$192.20K derived: sum of 3 quarters · filed 2019-02-22 | $7.80K 10-K · filed 2019-02-22 | $7.83M 10-K · filed 2018-02-23 | |
| 2017-09-30 | $917.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $1.15M derived: sum of 2 quarters · filed 2017-11-03 | $1.35M 10-Q · filed 2017-11-03 | -$10.77M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2017-06-30 | $233.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $433.00K 10-Q · filed 2017-08-04 | -$11.69M derived: sum of 3 quarters · filed 2018-02-23 | -$11.36M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2017-03-31 | $200.00K 10-Q · filed 2017-05-05 | -$11.92M derived: sum of 2 quarters · filed 2018-02-23 | -$11.59M derived: sum of 3 quarters · filed 2018-02-23 | -$11.50M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-12-31 | -$12.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | -$11.79M derived: sum of 2 quarters · filed 2018-02-23 | -$11.70M derived: sum of 3 quarters · filed 2018-02-23 | -$10.86M 10-K · filed 2018-02-23 | ||
| 2016-09-30 | $328.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $416.00K derived: sum of 2 quarters · filed 2016-11-09 | $1.26M 10-Q · filed 2016-11-09 | $1.28M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2016-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $935.00K 10-Q · filed 2016-08-05 | $949.00K derived: sum of 3 quarters · filed 2017-02-28 | -$10.70M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2016-03-31 | $847.00K 10-Q · filed 2016-05-06 | $861.00K derived: sum of 2 quarters · filed 2017-02-28 | -$10.79M derived: sum of 3 quarters · filed 2017-02-28 | -$11.60M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$11.63M derived: sum of 2 quarters · filed 2017-02-28 | -$12.44M derived: sum of 3 quarters · filed 2017-02-28 | -$10.88M 10-K · filed 2017-02-28 | -$10.60M 10-K · filed 2016-02-29 | |
| 2015-09-30 | -$11.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$12.46M derived: sum of 2 quarters · filed 2015-11-06 | -$10.90M 10-Q · filed 2015-11-06 | -$10.98M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2015-06-30 | -$808.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $751.00K 10-Q · filed 2015-08-06 | $668.00K derived: sum of 3 quarters · filed 2016-02-29 | $2.25M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2015-03-31 | $1.56M 10-Q · filed 2015-05-08 | $1.48M derived: sum of 2 quarters · filed 2016-02-29 | $3.06M derived: sum of 3 quarters · filed 2016-02-29 | $4.28M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $1.50M derived: sum of 2 quarters · filed 2016-02-29 | $2.72M derived: sum of 3 quarters · filed 2016-02-29 | $3.13M 10-K · filed 2016-02-29 | ||
| 2014-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $2.80M derived: sum of 2 quarters · filed 2014-11-10 | $3.22M 10-Q · filed 2014-11-10 | $3.60M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2014-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $1.63M 10-Q · filed 2014-08-08 | $2.02M derived: sum of 3 quarters · filed 2015-03-09 | |||
| 2014-03-31 | $412.00K 10-Q · filed 2014-05-12 | $798.00K derived: sum of 2 quarters · filed 2015-03-09 | ||||
| 2013-12-31 | $386.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $735.00K 10-K · filed 2015-03-09 | ||||
| 2013-09-30 | $349.00K 10-Q · filed 2013-11-08 | |||||
| 2012-12-31 | -$3.00M 10-K · filed 2014-03-10 | |||||
| 2012-06-30 | -$3.00M 10-Q · filed 2012-08-03 | |||||
| 2011-12-31 | $221.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |